United States - English - NLM (National Library of Medicine)

seagen inc. - brentuximab vedotin (unii: 7xl5iss668) (brentuximab vedotin - unii:7xl5iss668) - brentuximab vedotin 50 mg in 10.5 ml - adcetris is indicated for the treatment of adult patients with previously untreated stage iii or iv chl, in combination with doxorubicin, vinblastine, and dacarbazine. adcetris is indicated for the treatment of pediatric patients 2 years and older with previously untreated high risk chl, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide. adcetris is indicated for the treatment of adult patients with chl at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-hsct) consolidation. adcetris is indicated for the treatment of adult patients with chl after failure of auto-hsct or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-hsct candidates. adcetris is indicated for the treatment of adult patients with previously untreated salcl or other cd30-expressing ptcl, including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, d

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - brentuximab vedotin, quantity: 50 mg - injection, powder for - excipient ingredients: citric acid monohydrate; trehalose dihydrate; sodium citrate dihydrate; polysorbate 80 - hodgkin lymphoma,treatment of patients with previously untreated cd30+ stage iii or stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine, and dacarbazine (avd).,treatment of adult patients with cd30+ hl at higher risk of relapse or progression following asct.,treatment of adult patients with relapsed or refractory cd30+ hl:,1. following autologous stem cell transplant (asct) or,2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option.,peripheral t-cell lymphoma,treatment of adult patients with previously untreated cd30+ peripheral t-cell lymphoma (ptcl) in combination with cyclophosphamide, doxorubicin, and prednisone (chp).,treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (salcl).,cutaneous t cell lymphoma,treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Israel - English - Ministry of Health

takeda israel ltd - brentuximab vedotin - powder for concentrate for solution for infusion - brentuximab vedotin 50 mg/vial - brentuximab vedotin - adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl): 1. following autologous stem cell transplant (asct) or 2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following asct. adcetris is indicated for the treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy . adcetris is indicated for the treatment of adult patients with previously untreated stage iii or iv classical hodgkin lymphoma (chl), in combination with doxorubicin, vinblastine, and dacarbazine.adcetris is indicated for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

European Union - English - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastic agents - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd).adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct).adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option.systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl).adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl.cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Canada - English - Health Canada

seagen inc. - brentuximab vedotin - powder for solution - 50mg - brentuximab vedotin 50mg - antineoplastic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - brentuximab vedotin - powder for solution for infusion - 50mg

Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - brentuximab vedotin - injection, powder, for solution - 50mg/vial - brentuximab vedotin 50mg/vial

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - brentuximab vedotin 50mg;  ;   - powder for injection - 50 mg - active: brentuximab vedotin 50mg     excipient: citric acid monohydrate polysorbate 80 sodium citrate dihydrate trehalose dihydrate - hodgkin lymphoma treatment of adult patients with cd30+ hodgkin lymphoma (hl) at higher risk of relapse or progression following asct. treatment of adult patients with relapsed or refractory cd30+ hl: 1. following autologous stem cell transplant (asct) or 2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option.

Kenya - English - Pharmacy and Poisons Board

takeda pharma a/s po box 260, dybendal alle 10 2630 taastrup - brentuximab vedotin - powder for concentrate for solution for infus - 50mg per vial - brentuximab vedotin

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - brentuximab vedotin -